Abstract
Evaluation of the feasibility and efficacy of neoadjuvant concurrent chemoradiotherapy (CRT) with capecitabine and oxaliplatin in patients with locally advanced esophageal cancer. Forty-two patients were eligible for the study. The chemotherapy during CRT consisted of two cycles of intravenous oxaliplatin of 120 mg/m2 on day 1 and oral capecitabine 825 mg/m2 twice daily on days 1–14 at 3-week intervals. The radiotherapy (1.8 Gy/fraction/day to a total dose of 45 Gy) was delivered to the primary tumor site and regional lymph node. All patients completed the planned treatment. Overall clinical response rate was 54.8% with complete response in 16.7% while pathological response rate was 38%. Anemia was the commonest hematologic toxicity (52.3%) with grade 3 in 4.7%, and esophagitis was the commonest non-hematologic toxicity 59.5% with grade 3 and 4 in 9.5%. No treatment-related death was observed. After a median follow-up duration of 19 months, the 2-year survival rate was 42%, median survival time was 20 months (95%CI: 13.802-26.198), while 2-year progression-free survival (PFS) rate was 32.5% with median PFS time of 15 months (95%CI: 10.042-19.958). Neoadjuvant concurrent CRT with capecitabine and oxaliplatin was found to be well tolerated and effective in patients with locally advanced esophegeal cancer; however, these results should be further evaluated in a phase III study.
Similar content being viewed by others
References
Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Van Raemdonck D. Cancer of the esophagus and gastroesophegeal junction: potentially curative therapies. Surg Oncol. 2001;10:113–22.
Falk J, Carstens H, Lundell L, Albertsson M. Incidence of carcinoma of the oesophegus and gastric Cardia-Changes over time and geographical differences. Acta Oncol. 2007;46:1070–4.
Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in oesophegeal cancer: lessons from more than 1, 000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234(3):360–7. discussion 368–9.
Piessen G, Mariette C, Triboulet JP. Cervical and upper third thoracic oesophegeal carcinoma: a single pathological entity? Ann Chir. 2005;130(2):86–91.
Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for oesophegeal cancer. CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.
Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, et al. Proposed revision of the oesophegeal cancer staging system to accommodate pathologic response (PP) following pre-operative chemoradiation. Ann Surg. 2005;241:810–20.
Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in oesophegeal squamous cell carcinoma. Cancer. 2006;106:2119–27.
Byfield JE. Combined modality infusional chemotherapy with radiation. In: Lokich JJ, editor. Cancer Chemotherapy by Infusion. 2nd ed. Chigaco, IL: Percepta Press; 1990. p. 521–51.
AL-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy vs radiotherapy alone in patients with oesophegeal cancer: an intergroup study. J Clin Oncol. 1997;15:277–84.
Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, et al. Oxaliplatin in combination with protracted infusion fluorouracil and radiation: report of a clinical trial for patients with oesophegeal cancer. J Clin Oncol. 2002;20:2844–50.
Magné N, Fischel JL, Formento P, Etienne MC, Dubreuil A, Marcié S, et al. Oxaliplatin, 5-fluorouracil and ionizing radiation. Importance of the sequence and influence of the p53 status. Oncology. 2003;64:280–7.
Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–7.
Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948–53.
Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbonate in human cancer xenografts. Biochem Pharmacol. 1998;55:1091–7.
Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;20:1759–66.
Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (Capecitabine plus oxaliplatin : active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084–91.
World Health Organization. WHO handbook for reporting results of cancer treatment: WHO offset publication no 48. Switzerland: World Health Organization; 1979.
Cox JD, Stetz J, Aja TF. Toxicity criteria of the radiation therapy oncology group (RTOG). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CT CAE V. 3.0 development of comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.
Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.
Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, et al. Treatment outcomes of resected oesophegeal cancer. Ann Surg. 2002;236:376–84. discussion. 384–385.
Keighley MRB. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther. 2003;18(suppl. 3):7–30.
Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localised carcinoma of the oesophegus (Cochrane Review). in the Cochrane Library, Issue 1. Oxford, Update Softwer; 2003.
Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, et al. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br JCancer. 2008;99(7):1020–6.
van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A. First line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophegeal cancer: a phase II study. Br J Cancer. 2007;96:1348–52.
Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.
Ishikura S, Nihei K, Ohtsu A, et al. Long term toxicities after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic oesophegus. J Clin Oncol. 2002;21:2697–702.
Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the oesophegus: a Japan Esophegeal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). J pn J Clin Oncol. 2004;34:615–9.
Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the oesophegus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wahba, H.A., El-Hadaad, H.A. & Abd-Ellatif, E.A. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer. Med Oncol 29, 1693–1698 (2012). https://doi.org/10.1007/s12032-011-0001-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-0001-2